Indokem Q1 FY27 Results (BSE: 504092)
Signal: Growth reaccelerated
The read
Consolidated results show third straight quarter of YoY revenue growth (+12.2%) and PAT doubling, but EBITDA margin remains thin at ~2.3% and other income contributed over a quarter of pre-tax profit. The standalone margin (EBITDA 5.2%) is healthier but benefited from a single quarter's cost dynamic. The company is still emerging from a prolonged downturn — Q4FY25 showed strong inflection but Q1FY27 suggests the recovery is not yet broad-based.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹46.63 Cr | 12.2% | 2.5% |
| EBIT | ₹0.62 Cr | -17.3% | |
| Net profit | ₹1.07 Cr | 52.9% | |
| EPS | ₹0.38 | 52.0% | |
| EBIT margin | 1.3% |
P&L walk
Revenue rose 12.2% YoY to ₹46.63 Cr, but EBITDA margin contracted 16bps to 2.3% due to higher employee and other expenses — net profit growth was driven by lower tax and a modest other income contribution.
Key positives
- Consolidated revenue +12.2% YoY — third straight quarter of growth.
- Standalone EBITDA margin expanded 113bps YoY to 5.2%, driven by operating leverage.
- PAT more than doubled YoY on both standalone (+160.6%) and consolidated (+52.9%) bases.
- Revenue from subsidiaries added ~₹4.11 Cr, reflecting improved group-level diversification.
Key concerns
- EBITDA margin on consolidated basis contracted 16bps YoY to just 2.3% — thin by any measure.
- Other income contributed 27.1% of consolidated PBT — core operating margin is still marginal.
- Finance cost grew 22.4% YoY, outpacing revenue growth.
- QoQ PAT decline of 59.6% on standalone and 214.7% drop on consolidated from Q4 (though Q4 is audited year-end, not strictly comparable).
- Sales growth on standalone basis still came at -71.3% QoQ (sequential comparison skewed by Q4 annual figure).
Earnings quality: includes non-operating other income
Research and educational content only. Not investment advice.